Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MABTENANCE: Rituximab Maintenance vs Observation in Chronic Lymphocytic Leukemia
2009-013651-29Phase 3Completed
- Sponsor
- AGMT
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Rituximab maintenance with Observation only (2 arms). Primary endpoint: Progression-free survival. Started Dec 2009; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2009-013651-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013651-29.